There’s a new digital health revolving door.
in August 2021 and spread its employees around to various initiatives. The head of the division left the company.
Patel is only the latest to enter the new revolving door between Alphabet and federal regulatory agencies. Current FDA Commissioner Robert Califf is a former Alphabet senior advisor. And Google’s chief health officer Karen DeSalvo is the former director of the Office of the National Coordinator for Health Information Technology.Subscribe to get the best Verge-approved tech deals of the week.Please confirm your subscription to Verge Deals via the verification email we just sent you.
Norge Siste Nytt, Norge Overskrifter
Similar News:Du kan også lese nyheter som ligner på denne som vi har samlet inn fra andre nyhetskilder.
FDA, Abbott agree on plan to resume production of infant formula at Michigan plantBREAKING: FDA and Abbott Nutrition agree on plan to resume operations at its infant formula facility in Sturgis, Michigan, the company announces.
Les mer »
FDA could allow foreign-made infant formula to be shipped to USThe FDA could allow foreign-made infant formula to be shipped to the U.S. amid a shortage at the shelves. abc15
Les mer »
FDA to investigate delay in baby formula plant inspection, commissioner saysFood and Drug Administration Commissioner Robert Califf said Monday that the agency will investigate why it took so long to dispatch inspectors to the Abbott Nutrition baby formula plant in Michigan.
Les mer »
FDA Limits Use of J&J COVID Vaccine Over Blood Clot RiskThe FDA is limiting who can receive the Johnson & Johnson COVID-19 vaccine because of concerns about the risk of a rare blood clotting condition.
Les mer »
FDA and Abbott Nutrition Announce Plans to Safely Reopen Bacteria-Riddled Baby Formula PlantAfter operations resume, it could still be six to eight weeks until baby formula is back on the shelves, Abbott representatives confirmed.
Les mer »
Will the FDA change how it vets drugs following the Alzheimer's debacle?The accelerated approval of a controversial drug used to treat Alzheimer’s disease has triggered US lawmakers to push for more oversight from the FDA
Les mer »